| pubmed-article:19889936 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C0021054 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C0076080 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C2003855 | lld:lifeskim |
| pubmed-article:19889936 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:19889936 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19889936 | pubmed:dateCreated | 2010-1-1 | lld:pubmed |
| pubmed-article:19889936 | pubmed:abstractText | In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model. The combined treatment enhanced the tumor-specific immune responses and prolonged the survival more effectively than either single therapy in GL26 tumor-bearing animals. Apoptosis was induced in the tumors of the animals by the treatment with TMZ. Calreticulin (CRT) surface exposure was detected by immunofluorescence staining of TMZ-treated GL26 cells. TMZ chemotherapy increased tumor antigen cross-priming from tumor cells, leading to cross-priming of tumor antigen-specific CD4(+) T cells and CD8(+) T cells. This chemotherapy appeared to suppress the frequency of CD4(+) CD25(+) regulatory T cells (Treg). Moreover, this combined therapy resulted in an increase in the tumor infiltration of CD4(+) and CD8(+) T cells. Collectively, the findings of this study provide evidence that the combination of TMZ chemotherapy and treatment with DC-based vaccines leads to the enhancement of antitumor immunity through increased tumor-specific immune responses via the cross-priming of apoptotic tumor cell death mediated by CRT exposure and, in part, the suppression of Treg. Therefore, CRT exposure, regulatory T cells, and cross-priming by TMZ chemotherapy may be immunological factors related to the enhancement of the antitumor effects of chemoimmunotherapy in an experimental brain tumor model. | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19889936 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19889936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19889936 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19889936 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19889936 | pubmed:issn | 1556-679X | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:KimTai-GyuTG | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:HongYong-KilY... | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:KimChang-Hyun... | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:ParkJung-SunJ... | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:KimChung... | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:ParkSung-Dong... | lld:pubmed |
| pubmed-article:19889936 | pubmed:author | pubmed-author:ChungDong-Sup... | lld:pubmed |
| pubmed-article:19889936 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19889936 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:19889936 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19889936 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19889936 | pubmed:pagination | 143-53 | lld:pubmed |
| pubmed-article:19889936 | pubmed:dateRevised | 2010-9-27 | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:meshHeading | pubmed-meshheading:19889936... | lld:pubmed |
| pubmed-article:19889936 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19889936 | pubmed:articleTitle | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. | lld:pubmed |
| pubmed-article:19889936 | pubmed:affiliation | Department of Neurosurgery, Kangnam St Mary's Hospital, The Catholic University of Korea, Banpo-dong 505, Seochogu, Seoul 137-701, South Korea. | lld:pubmed |
| pubmed-article:19889936 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19889936 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
